Centauri Therapeutics

Centauri Therapeutics is a UK-based biotechnology company specialising in the discovery and development of novel immunotherapies for life-threatening infectious diseases and oncology. Founded in 2014 and located at Alderley Park in Cheshire, the company's core platform is the proprietary Alphamer® technology, which redirects naturally existing antibodies to treat serious diseases without requiring the immune system to generate new antibodies. This clinically validated mechanism gives Centauri a differentiated approach to tackling antimicrobial resistance (AMR), a global health crisis affecting the efficacy of existing antibiotics. The company's lead clinical candidate, CTX-187, targets Gram-negative bacterial infections and has received FDA Qualified Infectious Disease Product (QIDP) status. In 2026, Centauri extended its Series A round to £30 million, including a £6 million investment from the AMR Action Fund, to advance CTX-187 toward clinical trials.